These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 7757855)
21. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century. Kweder SL Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917 [No Abstract] [Full Text] [Related]
22. Regulatory experts debate FDA's authority. Young D Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140 [No Abstract] [Full Text] [Related]
23. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
24. Good law from tragic facts--Congress, the FDA, and preemption. Annas GJ N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383 [No Abstract] [Full Text] [Related]
25. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
26. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. Roberts R; Rodriguez W; Murphy D; Crescenzi T JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467 [TBL] [Abstract][Full Text] [Related]
27. Impossible? Outlawing state safety laws for generic drugs. Glantz LH; Annas GJ N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958 [No Abstract] [Full Text] [Related]
28. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients. Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845 [TBL] [Abstract][Full Text] [Related]
29. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
30. PLIVA v. Mensing: generic consumers' unfortunate hand. Lee SB Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916 [No Abstract] [Full Text] [Related]
31. The Supreme Court, preemption, and malpractice liability. Kesselheim AS; Studdert DM N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672 [No Abstract] [Full Text] [Related]
37. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues. Thomas JW J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021 [No Abstract] [Full Text] [Related]
38. Pharmaceuticals and medical devices: FDA oversight. Berry MD Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893 [No Abstract] [Full Text] [Related]
39. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly. Vladeck DC Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967 [No Abstract] [Full Text] [Related]
40. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]